Today: 7 February 2026
Subscribe
Browse Category

Investment Analysis News 1 January 2026

Texas Instruments stock today: TXN slides into 2026 after year-end chip selloff

Texas Instruments stock today: TXN slides into 2026 after year-end chip selloff

NEW YORK, January 1, 2026, 16:32 ET — Market closed Texas Instruments Incorporated shares closed down $1.92, or 1.1%, at $173.49 on Wednesday, the final trading day of 2025, with U.S. stock markets shut on Thursday for the New Year’s Day holiday. The stock traded between $173.10 and $176.12, while the iShares Semiconductor ETF (SOXX) — an exchange-traded fund that tracks a basket of chip stocks — fell 1.2% and the SPDR S&P 500 ETF (SPY) slipped 0.7%. New York Stock Exchange The year-end drop matters because Texas Instruments is widely treated as a bellwether for cyclical demand, particularly in
1 January 2026
·····
Nebius stock dips into New Year holiday as insider sale notice puts Jan. 2 in focus

Nebius stock dips into New Year holiday as insider sale notice puts Jan. 2 in focus

NEW YORK, January 1, 2026, 16:35 ET — Market closed Nebius Group N.V. (NBIS) shares slipped into the year-end close, last down about 1.7% at $83.71, as traders headed into a holiday shutdown and weighed a newly disclosed planned insider sale. SEC The move matters because there is no fresh price discovery today, with U.S. exchanges shut for New Year’s Day. The next read on risk appetite for high-beta AI infrastructure names comes when trading resumes on Friday, Jan. 2. Nasdaq Nebius is a Netherlands-based infrastructure company focused on cloud and tooling for AI workloads, according to Reuters’ company description.
1 January 2026
·····
Corcept Therapeutics stock tanks on FDA relacorilant setback — what happens next for CORT

Corcept Therapeutics stock tanks on FDA relacorilant setback — what happens next for CORT

NEW YORK, January 1, 2026, 3:46 PM ET — Market closed. Corcept Therapeutics (CORT.O) shares ended the last U.S. session down 50.4% at $34.80 after the Food and Drug Administration declined to approve the company’s drug relacorilant for a rare hormonal-disorder-related blood-pressure condition. StockAnalysis U.S. stock markets are closed on Thursday for New Year’s Day, leaving investors to digest the regulatory setback before trading resumes on Jan. 2. MarketWatch The decision matters because relacorilant was pitched as Corcept’s next growth driver beyond its existing Cushing’s franchise, and the FDA’s action resets expectations for when — or whether — the drug
1 January 2026
·····
KLA stock today: KLAC ends 2025 with a slide as chip-tool names cool; earnings next in focus

KLA stock today: KLAC ends 2025 with a slide as chip-tool names cool; earnings next in focus

NEW YORK, January 1, 2026, 15:29 ET — Market closed Shares of KLA Corp fell 2.3% to $1,215.08 at Wednesday’s close, outpacing declines in chip-tool peers Applied Materials, down 1.1%, and Lam Research, down 1.5%. The pullback matters because KLA is a bellwether for semiconductor manufacturing spending, selling process-control tools that help chipmakers spot defects and improve yields — the percentage of usable chips produced. Investors have leaned heavily into chip-linked names on the back of AI-driven demand, and the sector is now heading into the first major checkpoint of 2026: guidance for the next leg of capital spending. Wall
1 January 2026
·····
Applied Materials stock dips as new U.S. export licenses and China’s 50% tool rule reset focus for AMAT

Applied Materials stock dips as new U.S. export licenses and China’s 50% tool rule reset focus for AMAT

NEW YORK, January 1, 2026, 14:50 ET — Market closed. Applied Materials ended the last U.S. session down 1.15% at $256.99, with Wall Street shut on Thursday for the New Year’s Day holiday. The stock’s next catalyst is not a product launch or an earnings pre-release. It is policy: fresh signals from Washington and Beijing that could change how chipmakers buy — and where they buy — the expensive tools used to make semiconductors. That matters for Applied because it sells wafer-fab equipment, the specialized machines used to deposit, etch and measure layers on silicon wafers. Small shifts in export
1 January 2026
···
Basic materials stocks today: XLB ends 2025 lower as silver slumps, China PMI surprise in focus

Basic materials stocks today: XLB ends 2025 lower as silver slumps, China PMI surprise in focus

NEW YORK, January 1, 2026, 13:54 ET — Market closed U.S. basic materials stocks ended 2025 on a softer note, with sector ETFs slipping on Wednesday as investors took profits in metals and kept risk light into the New Year holiday. U.S. equity markets are closed on Thursday for New Year’s Day. New York Stock Exchange Why it matters now: materials shares tend to track swings in commodity prices and expectations for global growth, leaving them sensitive to fresh signals from China and the U.S. economy at the start of 2026. The sector is also coming off a year in
1 January 2026
·······
Bank of America stock ends 2025 down as Fed liquidity signal sets up Jan. 14 earnings test

Bank of America stock ends 2025 down as Fed liquidity signal sets up Jan. 14 earnings test

NEW YORK, January 1, 2026, 11:58 ET — Market closed Bank of America Corp (BAC.N) shares closed at $55.00 on Wednesday, down 0.51%, in the last U.S. session of 2025. U.S. stocks are closed on Thursday for the New Year’s Day holiday. Stooq+1 The pause leaves investors heading into bank earnings season with few fresh company catalysts and a sharp focus on rates. Bank of America has set Jan. 14 for its fourth-quarter results. Bank of America For big lenders, the key question is whether funding costs keep easing as the Fed cuts rates, or whether deposit pricing stays sticky.
1 January 2026
·····
Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

NEW YORK, January 1, 2026, 10:45 ET — Market closed. Corcept Therapeutics Inc (CORT) shares last ended Wednesday down 50.4% at $34.80 after the company said U.S. regulators were not ready to approve its drug relacorilant for a form of high blood pressure linked to hypercortisolism. U.S. stock markets are shut on Thursday for New Year’s Day. HCPLive The selloff matters because relacorilant was the company’s key near-term bet to broaden its commercial base beyond its current product, and the FDA’s response forces investors to reassess both timing and risk. It also sharpens focus on Corcept’s oncology program. In the
1 January 2026
·····
Eli Lilly stock ends 2025 lower as 2026 drug-price shifts and GLP-1 pill race come into focus

Eli Lilly stock ends 2025 lower as 2026 drug-price shifts and GLP-1 pill race come into focus

NEW YORK, January 1, 2026, 10:21 ET — Market closed Eli Lilly shares slipped 0.5% in Wednesday’s final session of 2025, closing at $1,074.68, before U.S. markets shut for the New Year’s Day holiday. StockAnalysis+1 Why it matters now: drugmakers typically reset U.S. list prices at the start of the year, and new data have put the industry’s pricing playbook back under a political microscope. Reuters reported drugmakers plan to raise list prices on at least 350 branded medicines in 2026, even as they cut prices on a handful of drugs. Reuters Lilly sits at the center of two investor
1 January 2026
····
ASX:PDI in focus after Robex shareholders back merger; approvals now in spotlight

ASX:PDI in focus after Robex shareholders back merger; approvals now in spotlight

NEW YORK, January 1, 2026, 09:22 ET — Market closed Predictive Discovery Ltd said Robex Resources shareholders voted 94.54% in favour of the companies’ proposed merger, clearing a key condition for the all-share deal, an exchange filing showed. “We are delighted with the strong support shown by Robex shareholders for the Transaction,” CEO and Managing Director Andrew Pardey said, adding the combined group expects production of more than 400,000 ounces of gold a year by 2029. Predictive said the transaction is expected to close in the first quarter of 2026, subject to Québec court approval and regulatory consents, including from
1 January 2026
···
Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

NEW YORK, January 1, 2026, 07:56 ET — Market closed Cytokinetics, Incorporated (CYTK.O) shares rose $2.17, or 3.5%, to $63.54 in the last trading session of 2025, after swinging between $60.93 and $64.43 on volume of about 1.85 million shares. U.S. markets were shut on Thursday for the New Year’s Day holiday. Yahoo Finance The year-end move keeps focus on the company’s pivot from clinical-stage developer to commercial operator, with investors looking for hard signals on pricing and early demand. For drug developers, the first few weeks of launch execution can reset expectations quickly. Cytokinetics has said Myqorzo is expected
1 January 2026
·····
Transocean stock (RIG) ends 2025 flat as oil slides; OPEC+ meeting in focus

Transocean stock (RIG) ends 2025 flat as oil slides; OPEC+ meeting in focus

NEW YORK, January 1, 2026, 06:57 ET — Market closed Transocean Ltd. shares ended Wednesday unchanged at $4.13, after trading between $4.11 and $4.21, with about 23.18 million shares changing hands, according to Investing.com data. Investing.com U.S. markets are closed on Thursday for New Year’s Day, leaving investors to lean on commodity signals and sector positioning for the next move in offshore drillers. That linkage matters because contractors such as Transocean sell rig time to oil producers, and confidence in multi-year offshore projects tends to rise and fall with expectations for crude prices. Oil ended 2025 on a weaker note,
1 January 2026
····
1 … 75 76 77 78 79 … 282

Stock Market Today

CapitaLand Investment share price jumps as CapitaLand REIT payouts roll in — what’s next for 9CI

CapitaLand Investment share price jumps as CapitaLand REIT payouts roll in — what’s next for 9CI

7 February 2026
CapitaLand Investment shares rose 1.3% to S$3.12 on Friday, bucking a 0.8% drop in Singapore’s benchmark index. CapitaLand Integrated Commercial Trust reported a 16.4% jump in second-half distributable income, while CapitaLand Ascendas REIT posted a 1.4% full-year rise. CapitaLand China Trust saw full-year DPU fall to 4.82 cents amid weaker yuan and occupancy. CLI reports FY2025 results on Feb. 11.
Keppel stock holds near 12-year high after profit jump, special dividend; buyback adds support

Keppel stock holds near 12-year high after profit jump, special dividend; buyback adds support

7 February 2026
Keppel shares closed at S$11.64 on Friday, up 0.17%, after surging 6.1% the previous day on stronger FY2025 profit and a larger dividend plan. The company bought back 151,400 shares for about S$1.74 million. Keppel reported a 29% rise in full-year profit to S$1.02 billion and proposed a total distribution of 47 cents per share, including a special dividend partly paid in Keppel REIT units.
Go toTop